Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDIOW vs CREVW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDIOW Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

CDIOW Overall Winner 6-Pillar Tally: CDIOW 0 – 0 CREVW (6 Tie) Matrix Metrics: CDIOW 2 – 1 CREVW

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. Warrant (CDIOW) is the stronger overall head-to-head candidate over Carbon Revolution Public Limited Company Warrant (CREVW) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CDIOW carries a Unified Composite Score of 35.2/100 (SELL) at $0.01 (N/M Forward P/E, N/A operating margin), whereas CREVW carries 39.1/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While CREVW currently prints a higher short-term Unified Composite Score (39.1/100 SELL vs. CDIOW 35.2/100 SELL), CDIOW captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Defensive Composite Rating Caution: Although CDIOW compares more favorably head-to-head, both CDIOW (35.2/100 SELL) and CREVW (39.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CDIOW is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.3); meanwhile CREVW is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDIOW vs CREVW
CDIOW NASDAQ Head-to-Head Winner
Cardio Diagnostics Holdings Inc. Warrant
In Vitro & In Vivo Diagnostic Substances
$0.01
-38.54% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.59β · 280% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 15.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -8.5%) with fading momentum, RSI 46
RSI-14: 46.3 · SMA20: $0.02 · SMA50: $0.02
CREVW NASDAQ
Carbon Revolution Public Limited Company Warrant
Institutional Equity
$0.00
-58.82% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.07β · 354% Vol
Unified Composite Score
39.1 / 100 SELL
Tech 45.0 Fund 51.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.0%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $0.01 · SMA50: $0.01

6-Pillar Scorecard Institutional Category Breakdown (CDIOW 0 – 0 CREVW)

Columns: Metric · CDIOW · CREVW
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role In Vitro & In Vivo Diagnostic Substances Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDIOW (2) vs CREVW (1)
Institutional Metric CDIOW CREVW Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
1% ($0–$0) 0% ($0–$0) Stronger Trend CDIOW
Beta / 30D Volatility
Risk Regime
1.59β · 280% Vol -0.07β · 354% Vol Lower Realized Risk CDIOW
Unified Institutional Score
Composite Signal
35.2 / 100 (SELL) 39.1 / 100 (SELL) Higher Composite CREVW
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDIOW +50.73 pp
CDIOW: -20.81% · CREVW: -71.54%
3M Horizon CDIOW +77.75 pp
CDIOW: -10.26% · CREVW: -88.01%
6M Horizon CDIOW +112.66 pp
CDIOW: +22.38% · CREVW: -90.28%
1Y Horizon CDIOW +112.66 pp
CDIOW: +22.38% · CREVW: -90.28%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDIOW vs CREVW. Trailing 12-month operating profitability (CDIOW N/A vs CREVW N/A) and valuation multiples (CDIOW N/M vs CREVW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CDIOW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CREVW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDIOW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDIOW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CREVW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CREVW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDIOW Moat Profile Cyclical / Execution-Driven Positioning
In Vitro & In Vivo Diagnostic Substances Operator
Competes within the In Vitro & In Vivo Diagnostic Substances value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CREVW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDIOW vs CREVW Key Questions & Quantitative Answers

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. Warrant (CDIOW) is the stronger overall head-to-head candidate over Carbon Revolution Public Limited Company Warrant (CREVW) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CDIOW carries a Unified Composite Score of 35.2/100 (SELL) at $0.01 (N/M Forward P/E, N/A operating margin), whereas CREVW carries 39.1/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CREVW currently prints a higher short-term Unified Composite Score (39.1/100 SELL vs. CDIOW 35.2/100 SELL), CDIOW captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Defensive Composite Rating Caution: Although CDIOW compares more favorably head-to-head, both CDIOW (35.2/100 SELL) and CREVW (39.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CDIOW is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.3); meanwhile CREVW is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDIOW and CREVW split Growth & Scale metrics: CDIOW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CREVW at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CDIOW generates N/A in USD-normalized revenue versus N/A for CREVW. In operating R&D and SG&A reinvestment, CDIOW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CREVW.

CDIOW and CREVW trade at balanced relative valuation multiples. CDIOW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CREVW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDIOW (N/A ROE) versus CREVW (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CDIOW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 280% Vol realized risk). By comparison, CREVW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 354% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.